0001493152-24-023195.txt : 20240607 0001493152-24-023195.hdr.sgml : 20240607 20240607172506 ACCESSION NUMBER: 0001493152-24-023195 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240603 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40023 FILM NUMBER: 241030755 BUSINESS ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: SUITE 100 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 8000 MARINA BLVD STREET 2: SUITE 100 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 8-K 1 form8-k.htm
false 0000109657 0000109657 2024-06-03 2024-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report:

(Date of earliest event reported)

 

June 3, 2024

 

 

 

GT Biopharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other Jurisdiction of Incorporation)

 

1-40023

  

94-1620407

(Commission File Number)   (IRS Employer Identification No.)

 

8000 Marina Blvd., Suite 100

Brisbane, CA 94005

(Address of Principal Executive Offices and zip code)

 

(800) 304-9888

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol(s)   Name of each Exchange on which registered
Common stock, $0.001 par value   GTBP   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 3, 2024, Manu Ohri’s employment as Chief Financial Officer at GT Biopharma, Inc. (the “Company”) was terminated.

 

In connection with Mr. Ohri’s termination, on June 3, 2024, the Company has appointed Alan L. Urban as the Company’s Chief Financial Officer. Mr. Urban, age 55, has previously served as a member of the Board of Directors of the Company from June 2022 to May 2023; as Chief Financial Officer for SRAX, Inc. (OTC: SRAX), a financial technology company, from March 2023 to July 2023; as Chief Financial Officer for Creek Road Miners, Inc. (formerly OTC: CRKR), a cryptocurrency mining company, from November 2021 to March 2023; and as Chief Financial Officer and Secretary for Research Solutions, Inc. (NASDAQ: RSSS), a SaaS and content provider in the scientific, technical and medical information space, from October 2011 to October 2021. Earlier in his career, Mr. Urban served as Chief Financial Officer and Senior Vice President of Finance and Accounting for ReachLocal, Inc. (NASDAQ: RLOC), an internet marketing company; and as Vice President of Finance and Treasurer for Infotrieve, Inc., a content provider in the scientific, technical and medical information space. He has been a Certified Public Accountant (currently inactive) since 1998. Mr. Urban received a B.S. in Business, with a concentration in Accounting Theory and Practice, from California State University, Northridge.

 

On June 7, 2024, the Company entered into an Employment Agreement with Mr. Urban (the “Employment Agreement”). The Employment Agreement is effective from June 3, 2024 (the “Effective Date”) and shall continue for a period of one year. The Employment Agreement shall automatically renew for successive one year periods unless and until either party provides sixty (60) days’ advance written notice prior to applicable renewal term. Pursuant to the Employment Agreement, Mr. Urban will receive an annual base salary of $375,000 and is eligible to earn an annual discretionary bonus of up to 40% of his annual base salary each calendar year during the term, subject to the achievement of applicable Company and individual performance goals, as determined in the Company’s sole discretion. Mr. Urban is eligible to receive a stock award of the Registrant’s Common Stock following the three months after the Effective Date. The Employment Agreement further provides that Mr. Urban will be eligible to receive any benefit and participate in any benefit plan generally available to employees of the Company.

 

The Company may terminate the Employment Agreement without Cause (as such term is defined in the Employment Agreement) at any time and Mr. Urban may terminate his employment for Good Reason (as such term is defined in the Employment Agreement) at any time. Upon a termination of Mr. Urban’s employment by the Company without Cause or by Mr. Urban for Good Reason, Mr. Urban will be entitled to receive (i) for a termination or resignation that occurs during the first six months following the Effective Date, a cash severance equal to two (2) months of Mr. Urban’s then current Annual Base Salary (as such term is defined in the Employment Agreement) or (ii) for a termination or resignation that occurs any time thereafter, a cash severance equal to five (5) months of Mr. Urban’s then current Annual Base Salary, in either case less deductions and withholding required by law, payable in a lump sum within seventy (70) days of the termination of employment (or such shorter period as may allow the severance payment to be exempt from Code Section 409A). Upon a termination of Mr. Urban’s employment by the Company for Cause or by Mr. Urban without Good Reason, Mr. Urban will be entitled to the Accrued Amounts (as such term is defined in the Employment Agreement).

 

The Employment Agreement also contains certain non-disclosure covenants that apply during his employment and thereafter.

 

The foregoing summary of the Employment Agreement is qualified in its entirety by reference to the full text of the agreement, which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

  Exhibit    
  Number   Description
       
  10.1*   Employment Agreement between the Company and Alan Urban, dated as of June 7, 2024.
       
  104   Cover Page Interactive Data File (embedded as Inline XBRL document).

 

*Registrant has omitted schedules and exhibits pursuant to Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GT BIOPHARMA, INC.
     
Date: June 7, 2024 By: /s/ Alan Urban
    Alan Urban
    Chief Financial Officer

 

 

 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of June 7th, 2024, by and between GT Biopharma, Inc. (the “Company”), and Alan Urban (“Employee”). This Agreement may sometimes refer to the Company or Employee singularly as a “Party” or collectively as the “Parties.”

 

Article I.
EMPLOYMENT and duties

 

1.1 Commencement of Employment. The Company agrees to employ Employee, and Employee hereby accepts employment with the Company, upon the terms and conditions set forth in this Agreement, commencing on June 3rd, 2024 (the “Effective Date”).

 

1.2 Term. The Employee’s employment with the Company under this Agreement will commence on the Effective Date and shall continue for a period of one (1) year (the “Initial Term”) unless either Party terminates the Employee’s employment in accordance with Sections 1.3, 1.4 or 1.5 below; provided that on the one (1) year anniversary of the Effective Date and each annual anniversary thereafter (such date and each annual anniversary thereof, a “Renewal Date”), the Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one (1) year (each a “Renewal Term” and, together with the Initial Term, the “Term”), unless either Party provides written notice of its intention not to extend the term of the Agreement at least sixty (60) days prior to the applicable Renewal Date. In addition, following the Initial Term, either party may terminate this Agreement in accordance with Sections 1.3, 1.4 or 1.5 below.

 

1.3 Termination by Employee for Good Reason. The Employee may terminate this Agreement and Employee’s employment at any time for Good Reason. For purposes of this Agreement, “Good Reason” means Employee voluntarily terminates Employee’s employment with the Company after the occurrence of one or more of the following circumstances, without Employee’s advance written consent: (i) a material reduction in Employee’s Annual Base Salary or (ii) any material diminution in the level of Employee’s job title. Any event described above shall constitute Good Reason only if Employee provides the Company with written notice of the basis for a Good Reason termination (and specifying in reasonable detail the actions or inactions giving rise thereto) within sixty (60) days of the initial actions or inactions of the Company giving rise to such Good Reason. The notice must specify an effective date of termination that is not less than thirty (30) days, nor more than forty-five (45) days, after the date of the written notice, and Employee agrees that should the Company remedy the basis as reasonably determined by Employee for such resignation prior to the effective date of termination specified in Employee’s written notice, then Employee’s resignation will not be considered a resignation for Good Reason.

 

1.4 Termination by the Company for Cause. The Company may terminate this Agreement and the Employee’s employment immediately and at any time for Cause. For purposes of this Agreement, “Cause” shall mean (i) poor performance, gross negligence or willful misconduct with respect to the performance of Employee’s duties for the Company, which, for clarity, shall include all duties expected to be performed by a competent and diligent Chief Financial Officer of a publicly listed company including but not limited to the preparation and submission of all filings and financial and accounting information on a timely basis; (ii) Employee’s breach or violation, in any material respect, of any agreement between Employee and the Company, or any policy of the Company, including but not limited to the Company’s Confidential Information and Invention Assignment Agreement; (iii) Employee’s commission of a material act of dishonesty or breach of trust with regard to the Company; or (iv) Employee’s performance of any act or omission with respect to which, if Employee were prosecuted, would constitute a felony or a misdemeanor involving a crime of dishonesty, fraud or moral turpitude. In all cases, Cause shall be determined in the Company’s sole discretion.

 

 

 

 

1.5 Notwithstanding the foregoing, (i) the Company may terminate the Agreement and Employee’s employment at any time without Cause by providing Employee with one (1) month’s notice in accordance with Section 4.5 below or pay in lieu thereof and (ii) the Employee may terminate the Agreement and Employee’s employment at any time without Good Reason by providing the Company with one (1) month’s notice in accordance with Section 4.5. The Parties acknowledge and agree that if Employee fails to provide one (1) month’s notice of the termination of this Agreement and Employee’s employment in accordance with the terms of this Agreement, it would be difficult or impossible to determine with precision the amount of damages that would or might be incurred by the Company as a result. It is therefore understood and agreed by the Parties that in such event, the Employee will be responsible for an amount equal to one (1) month of the Employee’s then current Annual Base Salary, which would be in the nature of liquidated damages, and not a penalty, and represent a reasonable estimate of fair compensation for the losses that may reasonably be anticipated from such breach. Nothing contained herein will be construed as prohibiting the Company from pursuing any other remedies available to the Company for such breach.

 

1.6 Position. Employee shall be employed as the Chief Financial Officer of the Company, an exempt position, and shall report to the Executive Chairman and Interim Chief Executive Officer of the Company (currently, Michael Breen). Employee shall perform such duties, and have such power, authority, functions, and responsibilities for the Company as are commensurate and consistent with this position, including, but not limited to all duties expected to be performed by a competent and diligent Chief Financial Officer of a publicly listed company, which shall include the preparation and submission of all filings and financial and accounting information on a timely basis, operating within such established guidelines, plans or policies as may be established, modified, or approved by the Chief Executive Officer of the Company from time to time. Employee’s principal place of employment will be the Employee’s home office located in California, subject to any necessary business travel within and outside the United States. Employee must inform the Company in a timely manner and receive consent before relocating out of California.

 

1.7 Other Business Affiliations. During Employee’s employment with the Company, Employee will devote Employee’s entire business time, attention, skill and energy on a full-time and exclusive basis to the business of the Company, and will perform the duties and carry out the responsibilities assigned to Employee to the best of Employee’s ability, in a diligent, trustworthy, businesslike and efficient manner for the advancement of the best interests of the Company. During Employee’s employment with the Company, Employee will not, without the prior written consent of the Company, assume any other employment, engage in any other business or occupation, become an officer, employee, agent or consultant for any other company, firm or individual, or otherwise devote any time to any business affiliation which would prevent Employee from performing, conflict with, or create an appearance of conflict with Employee’s duties and obligations under this Agreement.

 

Article II.
COMPENSATION AND BENEFITS

 

2.1 Annual Base Salary. As full compensation for the services rendered by Employee pursuant to this Agreement, Employee shall be paid a gross annual base salary of $375,000 (“Annual Base Salary”), less deductions and withholding required by law or approved by Employee, paid in accordance with the Company’s normal and customary payroll practices.

 

2

 

 

2.2 Reimbursable Expenses. Employee shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business expenses incurred by Employee in connection with the performance of Employee’s duties hereunder in accordance with the Company’s expense reimbursement policies and procedures. Any reimbursements by the Company to Employee of any eligible expenses under this Agreement, other than reimbursements that would otherwise be exempt from income or the application of Internal Revenue Code (the “Code”) Section 409A, (“Reimbursements”) will be made promptly and, in any event, on or before the last day of Employee’s taxable year following Employee’s taxable year in which the expense was incurred. The amount of any Reimbursements, and the value of any in-kind benefits to be provided to Employee under this Agreement, other than in-kind benefits that would otherwise be exempt from income or the application of Code Section 409A, during any of Employee’s taxable years will not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other of their taxable years. The right to Reimbursements, or in-kind benefits, will not be subject to liquidation or exchange for another benefit.

 

2.3 Bonus. Employee is eligible to earn an annual discretionary bonus (the “Annual Bonus”) equal to forty percent (40%) of the Annual Base Salary, less deductions and withholding required by law or approved by Employee, subject to the achievement of Company and individual performance goals, to be established by the Company, by December 31 of the immediately preceding calendar year, as determined in the Company’s sole discretion. For calendar year 2024, the Company will provide the applicable Company and individual performance goals on or shortly after the Effective Date. For the avoidance of doubt, the Annual Bonus in calendar year 2024, if earned, will be prorated based on the Effective Date. The Annual Bonus, if any, earned for a calendar year shall be paid to Employee as soon as reasonably practicable following the determination of the attainment level of the performance conditions applicable to the Annual Bonus, provided that such Annual Bonus will only be earned and payable if the Employee remains employed by the Company through the date on which the Annual Bonus is paid out.

 

2.4 Benefits. Employee will be eligible to participate in all Company health, medical, dental, disability and insurance plans and such other employee benefits, if any, as the Company may establish for its employees and as may be modified or terminated by the Company from time to time in accordance with the terms of the plans.

 

2.5 Equity Awards. As soon as reasonably practicable after the third month following the Effective Date, the Company shall consider Employee’s eligibility to be granted a long-term performance award over the shares of the common stock of the Company.

 

2.6 Vacation. Employee will be entitled to 20 days of vacation (“Vacation”) per full calendar year (prorated for partial years), to be taken for any reason, including vacation or other personal time away from work, at times agreed upon by Employee and the Company, subject to applicable law. Employee’s Vacation entitlement is not granted on the Effective Date, but rather will accrue on a pro-rata basis (i.e., at a rate of 1.67 days per month) with every month of active employment after the Effective Date. Employee’s accrued but unused Vacation will carry over from year to year. However, Employee may only accrue Vacation up to a maximum of one and one-half times the annual accrual amount. When the maximum accrual level is reached, accrual will cease until Employee has used previously accrued Vacation and their accrued but unused Vacation falls below the maximum accrual amount. Employee will not receive retroactive credit for any period of time in which Employee did not accrue Vacation because Employee had reached the maximum accrual leave. On termination of employment, the Company will pay Employee for any accrued but unused Vacation.

 

2.7 Paid Sick Leave. Employee will also be entitled to six (6) days each full calendar year (prorated for partial years), which will be subject to the terms of the Company’s sick time policy in effect at any time. Employee will not carry over unused paid sick leave from one year to the next and unused sick days will not paid out on termination of employment.

 

3

 

 

Article III.
Remuneration upon Termination of Employment.

 

3.1 Remuneration upon Termination by the Company without Cause or Resignation by the Employee with Good Reason. Upon termination of Employee’s employment with the Company for any reason, Employee will be entitled to: (a) any accrued and unpaid Annual Base Salary through the date of termination, (b) reimbursement for any business expenses properly incurred for which Employee shall not have been previously reimbursed, (c) any accrued but unpaid Vacation, and (d) any other amounts required by applicable law (collectively the “Accrued Amounts”). In addition, in the event of termination by the Company without Cause or resignation by the Employee with Good Reason, subject to the Employee complying with executing a separation and release agreement in a form satisfactory to the Company, Employee shall receive: (i) for a termination or resignation that occurs during the first six months following the Effective Date, a cash severance equal to two (2) months of the Employee’s then current Annual Base Salary or (ii) for a termination or resignation that occurs any time thereafter, a cash severance equal to five (5) months of the Employee’s then current Annual Base Salary, in either case less deductions and withholding required by law, payable in a lump sum within 70 days of the Employee’s termination of employment (or such shorter period as may allow the severance payment to be exempt from Code Section 409A).

 

3.2 Remuneration upon Termination by the Company with Cause or by the Employee without Good Reason. Upon termination of Employee’s employment by the Company with Cause or by the Employee without Good Reason, Employee will only be entitled to the Accrued Amounts.

 

3.3 No Further Obligations of the Company. Except as expressly provided in this Article 3, following the termination of Employee’s employment with the Company, the Company will have no further obligation or liability to Employee or Employee’s heirs, administrators or executors with respect to compensation, severance, bonus or any other benefits except as provided by any benefit plan or by law.

 

Article IV.
MISCELLANEOUS PROVISIONS

 

4.1 Conditions to Employment. This offer is contingent on:

 

a)Verification of Employee’s right to work in the United States, as demonstrated by Employee’s completion of the Form I-9 upon hire and Employee’s submission of acceptable documentation (as listed on the last page of the Form I-9) verifying Employee’s identity and work authorization within three (3) days of starting employment.

 

b)Employee signing the Confidential Information and Invention Assignment Agreement (“CIIAA”) attached hereto as Attachment A.

 

c)Employee signing the Mutual Arbitration Agreement attached hereto as Attachment B.

 

4.2 No Breach of Duty. Employee represents that Employee’s performance of this Agreement and employment with the Company does not and will not breach any agreement or duty to keep in confidence proprietary information acquired by Employee before their employment with the Company. Employee has not and will not enter into any agreement, either written or oral, in conflict with this Agreement. Employee represents that they are not currently restricted from being employed by the Company or entering into this Agreement.

 

4

 

 

4.3 Notice. All notices and other communications under this Agreement must be in writing and are deemed duly delivered when (a) delivered, if delivered personally or by nationally recognized overnight courier service (costs prepaid), (b) sent by electronic mail with confirmation of transmission (or, the first business day following such transmission if the date of transmission is not a business day), or (c) received or rejected by the addressee, if sent by United States of America certified or registered mail, return receipt requested; in each case to the following addresses and marked to the attention of the individual (by name or title) designated below (or to such other address, or individual as a Party may designate by notice to the other Parties):

 

  If to the Employee: Alan Urban

 

[****]

 

Email: [****]

 

  If to the Company: c/o GT Biopharma, Inc.

 

8000 Marina Blvd. Suite 100. Brisbane CA 94005

 

Attn: Michael Breen

 

Email: mb@gtbiopharma.com

 

4.4 Code Section 409A. The Parties intend that this Agreement and the benefits provided hereunder be interpreted and construed to be exempt from or to otherwise comply with Code Section 409A to the extent applicable thereto. Notwithstanding any provision of this Agreement to the contrary, this Agreement shall be interpreted and construed consistent with this intent, provided that the Company shall not be required to assume any increased economic burden in connection therewith. Although the Company intends to administer this Agreement so that it will be exempt from, or otherwise comply with, the requirements of Code Section 409A, the Company does not represent or warrant that this Agreement will be exempt from or otherwise comply with Code Section 409A, or any other provisions of federal, state, local, or non-United States laws. None of the Company, its affiliates, or their respective directors, officers, employees or advisors shall be liable to Employee (or any individual claiming a benefit through Employee) for any tax, interest, or penalties that Employee may owe as a result of compensation or benefits paid under this Agreement, and the Company and its affiliates shall have no obligation to indemnify, reimburse, or otherwise protect Employee from the obligation to pay any taxes pursuant to Code Section 409A or otherwise. For purposes of this Agreement, the terms “terminate,” “termination,” “termination of employment,” and variations thereof as used in this Agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A, to the extent necessary or advisable to comply with Code Section 409A. Notwithstanding any provision of this Agreement to the contrary, in the event that any payment to Employee or any benefit hereunder is made upon, or by reference to, Employee’s termination of employment, and Employee is a “specified employee” (as that term is defined under Code Section 409A) upon the Employee’s termination of employment, and provided further that such payment or benefit does not otherwise qualify for an applicable exemption from Code Section 409A, then no such payment or benefit shall be paid or commenced to be paid to Employee under this Agreement until the date that is the earlier to occur of: (i) Employee’s death, or (ii) six (6) months and one (1) day following Employee’s termination of employment (the “Delay Period”). Any payments which Employee would otherwise have received during the Delay Period shall be payable to Employee in a lump sum on the date that is six (6) months and one (1) day following the effective date of Employee’s termination.

 

5

 

 

4.5 Severability. If any term, provision, covenant or condition of this Agreement is held to be invalid, void, or unenforceable, the remainder of the provisions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby.

 

4.6 Entire Agreement; Employment Amendments; Waiver. This Agreement, together with the CIIAA and the Mutual Arbitration Agreement, contains the entire agreement and understanding between the Parties hereto concerning the subject matter hereof and supersede and replace all prior or contemporaneous agreements or understandings between the Parties. This Agreement may not be amended or modified in any manner, except by an instrument in writing signed by Employee and an authorized representative of the Company. Failure of either party to enforce any of the provisions of this Agreement or any rights with respect thereto or failure to exercise any election provided for herein shall in no way be considered to be a waiver of such provisions, rights or elections or in any way effect the validity of this Agreement. The failure of either party to exercise any of said provisions, rights or elections shall not preclude or prejudice such party from later enforcing or exercising the same or other provisions, rights or elections which it may have under this Agreement.

 

4.7 Successors and Assigns: Assignment. Except as otherwise provided in this Agreement, this Agreement, and the rights and obligations of the Parties, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives. The Company may assign any of its rights and obligations under this Agreement. Employee’s obligations under this Agreement are personal to Employee and may not be delegated.

 

4.8 Governing Law. This Agreement shall be governed by and construed in all respects in accordance with the laws of California, provided that disputes arising out of this Agreement will be subject to the Mutual Arbitration Agreement attached hereto as Attachment B and the Federal Arbitration Act (9 U.S.C. §§ 1 et seq.).

 

4.9 Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement.

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first above written.

 

“Employee”  

“Company”

         
    GT Biopharma, Inc.
         
By:   By:
  ALAN LOUIS URBAN     MICHAEL BREEN
  Title: EXECUTIVE CHAIRMAN & INTERIM CHIEF EXECUTIVE OFFICER

 

6

 

 

ATTACHMENT A

 

CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT

 

7

 

 

ATTACHMENT B

 

MUTUAL ARBITRATION AGREEMENT

 

8

 EX-101.SCH 3 gtbp-20240603.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 gtbp-20240603_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 gtbp-20240603_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 03, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 03, 2024
Entity File Number 1-40023
Entity Registrant Name GT Biopharma, Inc.
Entity Central Index Key 0000109657
Entity Tax Identification Number 94-1620407
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 8000 Marina Blvd.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Brisbane
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94005
City Area Code (800)
Local Phone Number 304-9888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol GTBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "*+QU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " BB\=8-!"",.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)^WJ"J';B^))07!!\1:2V=U@\X=DI-VW-XV[740?P&-F?OGF M&YA.!:%\Q.?H T8RF*XF.[@D5-BP U$0 $D=T,I4YX3+S9V/5E)^QCT$J3[D M'J'E? T626I)$F9@%18BZSNMA(HHR<<37JL%'S[C4&!: 0YHT5&"IFZ ]?/$ M<)R&#BZ &488;?HNH%Z(I?HGMG2 G9)3,DMJ',=Z7)5R,X?Y]=?_A=A*W79F?^ ML?%9L._@UUWT7U!+ P04 " BB\=8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M "*+QUB,B/ 36P0 !01 8 >&PO=V]R:W-H965T&UL MC9AK<^(V%(:_YU=HW$YG=X;$%RZ!%)@!FG7X0M@!-;,DKR1#^ M?8\,L=G4',,'\.V\?GS.\2N)_E:J%[UFS)#7)!9ZX*R-26]<5X=KEE!])5,F MX,Q2JH0:V%4K5Z>*T2@/2F(W\+R.FU NG&$_/S95P[[,3,P%FRJBLR2A:C=F ML=P.'-]Y._#,5VMC#[C#?DI7;,;,G^E4P9Y;J$0\84)S*8ABRX$S\F_&0=L& MY%?\Q=E6'VT3^R@+*5_LSF,T<#Q+Q&(6&BM!X6?#)BR.K1)P?#^(.L4];>#Q M]IOZ??[P\# +JME$QM]X9-8#I^N0B"UI%IMGN?V-'1XH!PQEK/-OLMU?VVHY M),RTDS6HV8W\ M4?-H@./"5F5F%)SE$&>&$[EAJN\:D+('W/ 0-MZ'!2?"?L_$%?&:#1)X0>O' M\7Q&^9L'7Q-2'MS+,H!<-F>]25@6'AWYCNJJB MP..7--8,X6@7'.WSDC%EBLN(W(F(0/-5Y@57RMLH[Z.Z1NH4;!U4\4X8;G;D MGL>,/&7)HKJY<0W_LN5Y01.AN2YHKL^A>68K;AL;4O9$D\H\X3H/\XLQE^F: M@@\UR*,(KQ"X;@'7/0=N I54- ;5B+V23VQ7A8?#QO5ZG?8U@]0JLWCE8 M<_I*'B-@XTL>TMS!3]<35^RU+OU.X+4\#,_W2L?TS@&$*DB52I6S-=;V4E*"XYRSB4PO<\#+!T?A_W[O> $[L'=9[+ MK:B$P^7&BNL%?5^ ']G* <'''?T]6]&$4R4W7(359<8U)R,,K1PC?-S:WZ-- MI3;@,G_S]/2;@2OVP)7;&%LY1OBXP>Z[+7[78QHG)4\'$S_Z:X,4Q :I(D$P?OU954N%#==,,O M1P0?-_"9C'G(#1]>>H4;+]*<4%@0^LDL*7!OG9NX)Y"$FI(AL:9RAP:?\![M=S12/; M>+-=LI"5;5QS:')W3VZNT=W M)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP M4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W M8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM M5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLY MS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B M'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P M:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X M3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3 MB.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3 M_ 102P,$% @ (HO'6)>*NQS $P( L !?3T\$MP> M:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5; M&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI" M/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V, MYU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8I MGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48 MY0]02P,$% @ (HO'6"0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB M688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4: MY$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[? M#'!X=/X!4$L#!!0 ( "*+QUAED'F2&0$ ,\# 3 6T-O;G1E;G1? M5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS M3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV M(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U M2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z M6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1 M.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( "*+ MQUB,B/ 36P0 !01 8 " @0T( !X;"]W;W)K# >&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" BB\=899!YDAD! #/ P $P @ &H$@ 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 "0 ) #X" #R$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://gtbiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm gtbp-20240603.xsd gtbp-20240603_lab.xml gtbp-20240603_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "GTBP", "nsuri": "http://gtbiopharma.com/20240603", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "gtbp-20240603.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "gtbp-20240603_lab.xml" ] }, "presentationLink": { "local": [ "gtbp-20240603_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://gtbiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-023195-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-023195-xbrl.zip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end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000109657 2024-06-03 2024-06-03 iso4217:USD shares iso4217:USD shares false 0000109657 8-K 2024-06-03 GT Biopharma, Inc. DE 1-40023 94-1620407 8000 Marina Blvd. Suite 100 Brisbane CA 94005 (800) 304-9888 false false false false Common stock, $0.001 par value GTBP NASDAQ false